Bertin Pharma and INDIGO Biosciences Sign Agreement for Distributing Nuclear Receptor Assay Kits in Europe
Over 40 product references to assay nuclear receptors are now available for European researchers during their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, or even endocrinology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161114006168/en/
Nuclear Receptor Assay kits distributed in Europe via Bertin Pharma and INDIGO Biosciences agreement (Photo: INDIGO Biosciences)
Innovative products to reduce time, cost and risk in drug discovery process
INDIGO Biosciences, leader in Nuclear Receptor Research, provides the world’s largest portfolio of Nuclear Receptor Assay kits using luciferase reporter technology. Those kits are all-inclusive, cell-based, robust, and ready to use for either screening small numbers of test compounds or HTS application.
Expansion to Europe
With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares.
Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation.
Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology.
“It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.” Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma
“We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO – INDIGO Biosciences
About INDIGO Biosciences
About Bertin Pharma
Fred Marroni (814)234-1919
Frédérique Vigezzi - Gootenberg, +33 (0)143 59 2984
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Meet Group Announces Closing of Lovoo Acquisition19.10.2017 20:58 | Pressemelding
The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006572/en/ The Meet Group anticipates this purchase will continue the momentum of its mission to meet the universal need for human connection through innovating, acquiring, and building the largest mobile portfolio of brands for meeting new people. The acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. “LOVOO is our third strategic acquisition in the last 12 months, and
Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms19.10.2017 20:00 | Pressemelding
Edgewater Networks, Inc., the market leader in Network Edge Orchestration, announces the upcoming availability of its SD-WAN offering targeted for Small to Medium Enterprises, a key market for service providers offering Unified Communications as a Service. Edgewater Networks’ SD-WAN solution is optimized for the BroadSoft BroadWorks® and BroadCloud® platforms and brings the benefits of this technology to the BroadSoft customer base. “As a new component of our Network Edge Orchestration platform, Edgewater Networks SD-WAN service allows BroadSoft customers to offer comprehensive end user service level agreements by ensuring that real-time communications are automatically routed to the best available Internet connection,” said Chris Kolstad, Edgewater Networks’ Vice President of Product Management. “Edgewater Networks’ SD-WAN offers a new revenue stream to service providers with a soluti
Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security19.10.2017 19:20 | Pressemelding
Business Wire today announced that it has successfully completed a Type 2 SOC 2 examination of its BW Connect and HQ systems. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006400/en/ The attestation engagement report, conducted by the independent CPA firm Schellman & Company, LLC, confirms that Business Wire has met the standards established by the American Institute of Certified Public Accountants [AICPA] Trust Services Principles related to security. BW Connect is Business Wire’s proprietary web-based order-entry system; HQ provides web-hosting services for online newsrooms, and investor relations hubs for publicly-traded companies. The examination, conducted during the review period February 1, 2017 through July 31, 2017, focused on Business Wire adherence to the Trust Service Principle/Secu
Pharnext: First-Half 201719.10.2017 17:30 | Pressemelding
Regulatory News: Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its first-half 2017 financial results. Daniel Cohen, M.D., Ph.D. Co-Founder and CEO said of activity for the first half of 2017: "Activity in the first-half of the year was very dense; we implemented two prominent strategic partnerships with the biotech company Galapagos and the Tasly Group, one of the top ten pharmaceutical companies in China. Our flagship product, PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, is nearing the end of Phase 3, which is slated for the second half of 2018. We confirm our target of taking the product to market by 2019." A half-year marked by strategic agreements
Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 201819.10.2017 16:58 | Pressemelding
Tickets for the FEI World Equestrian GamesTM Tryon 2018 (WEG) are now on sale to the public online at www.tryon2018.com. With more than 500,000 people expected to attend the 2018 Games, the 12-day spectacle of equestrian champions is one of the biggest events on the global sporting calendar and will be the largest equestrian event in North Carolina’s history. Mark Bellissimo, CEO of host venue Tryon International Equestrian Center (TIEC) in Tryon, NC, USA, said: “Demand from the event is way beyond our expectations and it would not surprise me if this event were to sell out early. We have experienced unprecedented demand, far bigger than we ever anticipated. There is tremendous appetite for this event, so we encourage people to buy now.” Tickets for the WEG include the following options: a standard Day Pass, Individual Event Pass, All Session Discipline Pas
SFL – Third-Quarter 2017 Financial Information19.10.2017 16:30 | Pressemelding
Regulatory News: SFL (Paris:FLY): Rental income: €147.8 million, up 3.3% like-for-like Consolidated revenue by business segment (€000’s) 2017 (9 months) 2016 (9 months)
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom